Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 2/20 | 0.40 |
| ▸ | RORB | Q92753 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 8/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 7/20 | 0.35 |
| ▸ | RORC | P51449 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7205333 | 0.75 | MEN1 (0.49) | SLC9A1HSD17B1HSD17B2SMN1; SMN2 | |
| SCHEMBL5550230 | 0.75 | FNTA (0.47) | SLC9A1 | |
| SCHEMBL5549184 | 0.71 | LTB4R (0.42) | SLC9A1RORBHSD17B1HSD17B2RORC | |
| SCHEMBL5023267 | 0.71 | CSNK2A2 (0.43) | RORBHSD17B1HSD17B2MAPTNPC1 | |
| SCHEMBL5022746 | 0.71 | IP6K1 (0.52) | MAPTSMN1; SMN2 | |
| SCHEMBL5023770 | 0.69 | KDM4E (0.52) | RORB | |
| SCHEMBL5016820 | 0.66 | ALOX15 (0.45) | HSD17B1HSD17B2RORCPOLB | |
| SCHEMBL4289870 | 0.65 | HSD17B10 (0.39) | HSD17B1 | |
| SCHEMBL4296470 | 0.65 | MEN1 (0.42) | HSD17B1HSD17B2POLBSMN1; SMN2 | |
| SCHEMBL11954832 | 0.64 | FNTA (0.39) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150973-B1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-6710209-B2 | INHIBITING FARNESYL PROTEIN TRANSFERASE. | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | SLC9A1 2318/4885RORB 2169/4885HSD17B1 2356/4885 |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | SLC9A1 2318/4885RORB 2169/4885HSD17B1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.